In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including:Threshold of CD30 positivity useful to inform brentuximab vedotin use in patients with CTCL and PTCLManaging relapsed mycosis fungoides after allogeneic SCTExperience with ALK inhibition in ALCL with central nervous system metastasesManaging refractory pruritus in CTCLRole of PI3K inhibitors in frontline and relapsed/refractory PTCLWhen to consider SCT in CTCL cycling through monotherapiesPresenters:Steven M. Horwitz, MDMemberMemorial Sloan Kettering Cancer CenterAttending PhysicianMemorial HospitalProfessor of MedicineWeill Cornell Medical College New York, New YorkFrancine Foss, MDProfessor of Medical OncologyYale Cancer CenterYale University School of MedicineNew Haven, ConnecticutBarbara Pro, MDProfessor of MedicineDivision of Hematology/OncologyNorthwestern UniversityChicago, IllinoisLink to the complete program, including downloadable slidesets, an expert commentary, and on-demand webcast, and healthcare professional resource guide:https://bit.ly/3AKJE5s

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related